Cantor Fitzgerald cut shares of Pfenex (NASDAQ:PFNX) from an overweight rating to a neutral rating in a report issued on Monday, Zacks.com reports.
A number of other analysts also recently weighed in on PFNX. BidaskClub downgraded shares of Pfenex from a buy rating to a hold rating in a report on Saturday, July 25th. William Blair downgraded shares of Pfenex from an outperform rating to a market perform rating in a report on Friday, August 14th.
Shares of Pfenex stock opened at $12.60 on Monday. The company has a 50 day moving average of $8.77 and a 200-day moving average of $8.81. Pfenex has a 1-year low of $5.26 and a 1-year high of $14.00.
Pfenex Company Profile
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.
Read More: Debt-To-Equity Ratio
Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.